Unlocking the potential of signature-based drug repurposing for anticancer drug discovery
Archives of Biochemistry and Biophysics · 2024-11 · 761 · 110150
DOI: 10.1016/j.abb.2024.110150 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archives of Biochemistry and Biophysics, 2024-11. Verfasst von Sruti Biswal und 1 weiteren Autor:innen. Beteiligte Einrichtung: RNAi and Functional Genomics Lab., Department of Life Science, National Institute of Technology Rourkela, Rourkela, 769008, Odisha, India. Hauptthemen laut MEDLINE: Drug Repositioning, Antineoplastic Agents, Neoplasms, Drug Discovery. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 166 Literaturangaben. Gefördert von: University Grants Commission.
Abstract (Originalsprache)
Cancer is the leading cause of death worldwide and is often associated with tumor relapse even after chemotherapeutics. This reveals malignancy is a complex process, and high-throughput omics strategies in recent years have contributed significantly in decoding the molecular mechanisms of these complex events in cancer. Further, the omics studies yield a large volume of cancer-specific molecular signatures that promote the discovery of cancer therapy drugs by a method termed signature-based drug repurposing. The drug repurposing method identifies new uses for approved drugs beyond their intended initial therapeutic use, and there are several approaches to it. In this review, we discuss signature-based drug repurposing in cancer, how cancer omics have revolutionized this method of drug discovery, and how one can use the cancer signature data for repurposed drug identification by providing a step-by-step procedural handout. This modern approach maximizes the use of existing therapeutic agents for cancer therapy or combination therapy to overcome chemotherapeutics resistance, making it a pragmatic and efficient alternative to traditional resource-intensive and time-consuming methods.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- RNAi and Functional Genomics Lab., Department of Life Science, National Institute of Technology Rourkela, Rourkela, 769008, Odisha, India.
- RNAi and Functional Genomics Lab., Department of Life Science, National Institute of Technology Rourkela, Rourkela, 769008, Odisha, India. Electronic address: vivek.iitian@gmail.com.
Förderung
- University Grants Commission
Zitieren
APA
Biswal, S., & Mallick, B. (2024). Unlocking the potential of signature-based drug repurposing for anticancer drug discovery. Archives of Biochemistry and Biophysics, 761, 110150. https://doi.org/10.1016/j.abb.2024.110150
Vancouver
Biswal S, Mallick B. Unlocking the potential of signature-based drug repurposing for anticancer drug discovery. Archives of Biochemistry and Biophysics. 2024;761:110150. doi:10.1016/j.abb.2024.110150
BibTeX
@article{Biswal2024,
author = {Biswal, Sruti and Mallick, Bibekanand},
title = {Unlocking the potential of signature-based drug repurposing for anticancer drug discovery},
journal = {Archives of Biochemistry and Biophysics},
year = {2024},
volume = {761},
pages = {110150},
doi = {10.1016/j.abb.2024.110150}
}
EUVIMED